Richter syndrome results from the transformation of chronic lymphocytic leukemia (CLL) into a rapidly progressing diffuse large B cell lymphoma (DLBCL). It is a rare cancer and there are still few data on the efficacy and safety of CAR-T in patients with Richter syndrome, although there is some evidence suggesting that patients with Richter syndrome may benefit from these therapies.
A project was launched to better understand the efficacy and safety of CAR-T cells in patients diagnosed with Richter syndrome. This work was initiated in February 2022 by Professor Romain Guieze, hematologist at the Clermont-Ferrand University Hospital, and member of LYSA. This project uses data from the DESCAR-T registry and from patient medical records to clarify aspects of disease history and prognosis. Statistical analyses are carried out by LYSARC.
To patients in the DESCAR-T registry, and more particularly those initially diagnosed with Richter syndrome, if you would like more information about the processing of your data in the DESCAR-T Registry, you can contact the doctor at your care center for your CAR-T treatment or make a request at dpo@lysarc.org. You can also find more details your rights regarding your personal data in the homepage, in the section “I am participating or have participated in a clinical trial“, or in the Patient Information Leaflet you received at the time of your inclusion in the registry.